Mar 16, 2017

Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session With More Than 10 Presentations

First Ever Scientific Presentation of Abiomed's Impella® Quality (IQ) Assurance Program

DANVERS, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 10 presentations, including a late-breaking clinical research presentation, featuring the Impella® line of heart pumps, in addition to 17 poster presentations scheduled during the American College of Cardiology's 66th Annual Scientific Session, March 17-19 at the Walter E. Washington Convention Center in Washington, DC.

Abiomed is committed to improving outcomes in Protected PCI and cardiogenic shock through technology and innovation, excellence in education, clinical research, and appropriate and standardized use.  The following initiatives are planned for ACC:

The schedule for ACC symposia is included below. Additional Impella-related presentations and poster sessions are anticipated.  

The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP)
Marriott Marquis, Marquis Ballroom, Salon 5, Level M2
Thursday, March 16 | 6:30-9:00 PM
Navin K. Kapur, MD
William L. Lombardi, MD
James M. McCabe, MD
Ajay J. Kirtane, MD, SM

A Changing Approach to Percutaneous Hemodynamic Support: Decisions, Devices and Results
Marriott Marquis, Marquis Ballroom, Salon 5, Level M2
Saturday, March 18 | 6:15-7:45 AM
Navin K. Kapur, MD
William O'Neill, MD
Ajay Srivastava, MD
Eric Velazquez, MD


The Impella 2.5®, Impella CP® and Impella 5.0® are FDA-approved heart pumps used to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP® device, is approved to treat certain patients experiencing right heart failure. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com.

The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries.

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

**For further information please contact: 

Adrienne Smith
Senior Director, Public Relations and Corporate Communications

Ingrid Goldberg
Director, Investor Relations